Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GeneSoft Inc.
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?
Hikma has made the next move to build up its nascent US biosimilars business by striking a deal with Gedeon Richter for its denosumab candidate.
- Gene Therapy, Cell Therapy